Skip to content
HowShorted

OCULAR THERAPEUTIX, INC short interest in 2021

In 2021, OCULAR THERAPEUTIX, INC's disclosed short interest ran from 7.56% of shares outstanding on 15 Jan 2021 to 4.19% on 31 Dec 2021, a change of -3.37 percentage points. The year's high was 9.29% on 28 May 2021 and its low 4.19% on 31 Dec 2021, averaging 6.74% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.46 days on 15 Jun 2021. Full history: OCULAR THERAPEUTIX, INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for OCULAR THERAPEUTIX, INC in 2021

2021 in figures

Start of year
7.56% (15 Jan 2021)
End of year
4.19% (31 Dec 2021)
Change
-3.37 pp
High
9.29% (28 May 2021)
Low
4.19% (31 Dec 2021)
Average
6.74%
Highest days to cover
9.46 (15 Jun 2021)
SEC filings marked
11

Every report in 2021

OCULAR THERAPEUTIX, INC short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20217.56%7.64results (8-K)
29 Jan 20216.43%5.63
12 Feb 20216.66%8.26
26 Feb 20217.10%3.73
15 Mar 20217.06%5.2910-K filed, results (8-K)
31 Mar 20216.77%6.32
15 Apr 20216.31%8.05
30 Apr 20217.08%3.71results (8-K)
14 May 20217.83%4.1810-Q filed, results (8-K)
28 May 20219.29%7.64
15 Jun 20218.48%9.46
30 Jun 20217.64%6.16
15 Jul 20217.56%9.46
30 Jul 20217.56%6.79results (8-K)
13 Aug 20217.49%7.3610-Q filed, results (8-K)
31 Aug 20217.39%7.45
15 Sep 20217.61%8.68
30 Sep 20216.80%7.20
15 Oct 20216.17%3.33
29 Oct 20215.26%1.92
15 Nov 20214.91%3.2710-Q filed, results (8-K)
30 Nov 20214.22%3.82
15 Dec 20214.39%4.45
31 Dec 20214.19%4.23

See also: OCULAR THERAPEUTIX, INC's full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.